NCR 300
Alternative Names: NCR-300Latest Information Update: 18 Jul 2024
At a glance
- Originator Nuwacell Biotechnologies
- Developer Beijing Friendship Hospital; Nuwacell Biotechnologies
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Epstein-Barr virus infections; Haemophagocytic lymphohistiocytosis
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 15 Jul 2024 Clinical trials in Epstein-Barr virus infections (Treatment-experienced) in China (IV) (NCT06491719)
- 15 Jul 2024 Clinical trials in Haemophagocytic lymphohistiocytosis (Treatment-experienced) in China (IV) (NCT06491719)
- 11 Jun 2024 Preclinical trials in Acute myeloid leukaemia in China (Parenteral) (Nuwacell Biotechnologies website, June 2024)